Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary...

Area of Science:

• Cardiology
• Clinical Medicine
• Epidemiology

Background:

• Atrial fibrillation (AF) is a common complication following ST-elevation myocardial infarction (STEMI).
• Understanding the incidence, timing, and impact of AF is crucial for patient management post-primary percutaneous coronary intervention (PCI).

Purpose of the Study:

• To determine the incidence and timing of AF in STEMI patients undergoing primary PCI.
• To describe antithrombotic therapy use in these patients.
• To evaluate the association of new-onset AF with 90-day mortality and other clinical outcomes.

Main Methods:

• Analysis of 5745 STEMI patients treated with primary PCI from the APEX-AMI registry.
• Assessment of AF prevalence at baseline, during hospitalization, and at discharge.
• Evaluation of new-onset AF incidence and its association with mortality and secondary outcomes using adjusted hazard ratios.

Main Results:

• New-onset AF developed in 6.3% of patients, with an incidence of 9.3 cases per 1000 patient-days.
• New-onset AF was independently associated with increased 90-day mortality (aHR 1.81) and higher risks of shock, heart failure, and stroke.
• Suboptimal antithrombotic therapy use was observed, with 55% of AF patients not receiving oral anticoagulation at discharge, and only 39% of high-stroke-risk patients receiving it.

Conclusions:

• New-onset AF is a significant predictor of adverse outcomes, including mortality, in STEMI patients treated with primary PCI.
• There is a critical need to optimize antithrombotic therapy management in AF patients post-MI.
• AF serves as a marker for increased risk and warrants closer monitoring and tailored treatment strategies.